<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367262</url>
  </required_header>
  <id_info>
    <org_study_id>13736</org_study_id>
    <secondary_id>I4O-MC-BACD</secondary_id>
    <nct_id>NCT01367262</nct_id>
  </id_info>
  <brief_title>Disposition of 14C-LY2886721 Following Oral Administration in Healthy Human Subjects</brief_title>
  <official_title>Disposition of [14C]-LY2886721 Following Oral Administration in Healthy Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label study being conducted to determine the metabolism and physiological disposition
      of radiolabeled LY2886721 after a single dose in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Urinary and Fecal Excretion of LY2886721 Radioactivity Over Time</measure>
    <time_frame>Baseline up to 9 days post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of LY2886721 and radioactivity</measure>
    <time_frame>Predose, up to 96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration- time curve (AUC) of LY2886721 and radioactivity</measure>
    <time_frame>Predose, up to 96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of LY2886721 and the metabolites of LY2886721 in urine, and feces</measure>
    <time_frame>Baseline up to 9 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Radiolabeled LY2886721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 25 mg oral dose containing 80 microcuries of radiolabeled LY2886721</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2886721</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Radiolabeled LY2886721</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males as determined by medical history and physical examination

          -  Males will be sterile (including vasectomy) or if the subject is not sterile and is
             sexually active, he will agree to use from Check-in until 3 months after
             exit/discharge, 1 of the following approved methods of contraception: a male condom
             with spermicide, a sterile sexual partner, use by female sexual partner of an
             intrauterine device with spermicide, a female condom with spermicide, contraceptive
             sponge with spermicide, a diaphragm with spermicide, a cervical cap with spermicide,
             or oral, implantable, transdermal, intravaginal, or injectable contraceptives

          -  Have a body mass index of 19 to 30 kg/m2

          -  Have clinical laboratory test results within normal reference range for the population
             or investigator site, or results with acceptable deviations that are judged to be not
             clinically significant by the investigator

          -  Have venous access sufficient to allow for blood sampling

          -  Have normal blood pressure and heart rate (sitting)

          -  Experience a minimum of at least 1 bowel movement per day

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

          -  Have given written informed consent approved by Lilly and the institutional review
             board (IRB) governing the site

        Exclusion Criteria:

          -  Are currently enrolled in, have completed, or discontinued within the last 30 days
             from, a clinical trial involving an investigational product other than the
             investigational product used in this study; or are concurrently enrolled in any other
             type of medical research judged not to be scientifically or medically compatible with
             this study

          -  Have known allergies to LY2886721, related compounds, or any components of the
             formulation

          -  Are persons who have previously received the investigational product in this study,
             have completed or withdrawn from this study or any other study investigating LY2886721

          -  Have a Bazett's corrected QT (QTcB) interval value of &gt;450 msec (males) or any
             abnormality in the 12-lead Electrocardiograph(ECG) increases the risks associated with
             participating in the study

          -  Have an abnormal blood pressure

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV
             antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Intend to use prescription medication, over-the-counter medication, or herbal
             preparations containing St. John's Wort, kava, garlic, ginger, ginko biloba, or guarna
             within 14 days prior to admission

          -  Eating of grapefruit or grapefruit-containing foods, or drinking grapefruit-containing
             juices within 7 days prior to dosing or any time during the study

          -  Have used any tobacco- or nicotine-containing products (including, but not limited to,
             cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or
             nicotine gum) within 6 months prior to dosing

          -  Have donated blood of more than 500 mL within the last month

          -  Have an average weekly alcohol intake that exceeds 21 units per week (males up to age
             65), or are unwilling to stop alcohol consumption from 48 hours prior to check-in
             until end of study (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz
             or 45 mL of distilled spirits)

          -  Show evidence of significant active neuropsychiatric disease, in particular evidence
             of significant medical or psychiatric illness within the past 12 months. Have any
             other condition that would preclude participation in the study

          -  Have a history or presence of epilepsy, a history of seizures, any known brain
             abnormalities, and a history of significant brain injury

          -  Have participated in a 14C-study within the last 6 months prior to Check-in for this
             study. The total exposure from this study and the previous study must be within the
             Code of Federal Regulations (CFR) recommended levels considered safe (per 21 CFR
             361.1), less than 5,000 mrem/year whole body annual exposure

          -  Exposure to significant radiation within 12 months prior to dose (for example, serial
             X-ray or computed tomography scans, barium meal, current employment in a job requiring
             radiation exposure monitoring)

          -  Have a history of clinically significant adverse drug reactions or &quot;drug allergy&quot; to
             more than 3 types of systemically administered medications (all penicillins and
             cephalosporins may be considered 1 type of medication for this purpose)

          -  Have a history of, or current, significant ophthalmological disease

          -  Have evidence of active renal disease (for example, diabetic renal disease, polycystic
             kidney disease) or creatinine clearance of &lt;80 mL/min (as calculated by
             Cockcroft-Gault equation): Men: (140 - age) x (weight in kg)72 x (serum creatinine in
             mg/dL)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>August 9, 2011</last_update_submitted>
  <last_update_submitted_qc>August 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <keyword>Absorption</keyword>
  <keyword>Distribution</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Excretion</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

